Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
Elevation Oncology (ELEV) Stock Price & Analysis
163 Followers
ELEV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $5.89
Previous Close$3.7
Volume539.40K
Average Volume (3M)1.03M
Market Cap
$202.16M
Enterprise Value$149.19M
Total Cash (Recent Filing)$83.11M
Total Debt (Recent Filing)$30.14M
Price to Earnings (P/E)-3.6
Beta1.33
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding54,638,262
10 Day Avg. Volume1,129,260
30 Day Avg. Volume1,028,559
Standard Deviation0.79
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)3.69
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.84
Forecast
1Y Price Target
$7.75Price Target Upside107.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Elevation Oncology News
PremiumCompany Announcements
Lori Hu Resigns, Darcy Mootz Joins Elevation Oncology Board
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressInitial safety and efficacy data for EO-3021 is expected, which could indicate reduced toxicity and improved patient tolerance, showcasing potential for differentiation especially in terms of tolerability.
Financial StabilityExtended cash runway into 2026 demonstrates prudent financial management and provides financial stability for the near future.
Therapeutic AdvancementsPreclinical data on HER3-targeting ADC program showed promising antitumor activity, providing a solid foundation for further development and potential treatment advancements in HER3-expressing tumors.
Bears Say
Clinical Trial RisksRisks include clinical, partnership, regulatory, and commercial challenges that could impact the company's future success.
Financial PerformanceThe company reported no revenues and a net loss of $0.23 per diluted share.
Trial Outcome UncertaintyThe efficacy of Claudin 18.2 ADCs in U.S. trials remains uncertain, with factors like different patient demographics and toxicity profiles to consider.
---
Ownership Overview
21.57% Insiders
2.83% Mutual Funds
3.06% Other Institutional Investors
72.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $0.36 and its highest was $5.89 in the past 12 months.
What is Elevation Oncology’s market cap?
Currently, no data Available
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is Aug 01, 2024 which is in 86 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on May 02, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.028.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elevation Oncology have?
Elevation Oncology has 54,638,264 shares outstanding.
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -4.5%.
Which hedge fund is a major shareholder of Elevation Oncology?
Among the largest hedge funds holding Elevation Oncology’s share is Aisling Capital Management LP. It holds Elevation Oncology’s shares valued at 2M.
---
Elevation Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.75 (107.22% Upside)
$7.75 (107.22% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 66%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.01%
12-Months-Change
Fundamentals
Return on Equity
-71.82%
Trailing 12-Months
Asset Growth
41.70%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
---
ELEV Stock 12 Months Forecast
Average Price Target
$7.75
▲(107.22% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+12.29%
reiterated a buy rating 4 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +12.29% per trade.
---